European Case Law Identifier: | ECLI:EP:BA:2009:T046206.20090701 | ||||||||
---|---|---|---|---|---|---|---|---|---|
Date of decision: | 01 July 2009 | ||||||||
Case number: | T 0462/06 | ||||||||
Application number: | 01997102.7 | ||||||||
IPC class: | A61K 31/335 | ||||||||
Language of proceedings: | EN | ||||||||
Distribution: | C | ||||||||
Download and more information: |
|
||||||||
Title of application: | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | ||||||||
Applicant name: | Merck & Co., Inc. | ||||||||
Opponent name: | - | ||||||||
Board: | 3.3.01 | ||||||||
Headnote: | - | ||||||||
Relevant legal provisions: |
|
||||||||
Keywords: | Unity of invention (yes) Substantial procedural violation (no) |
||||||||
Catchwords: |
- |
||||||||
Cited decisions: |
|
||||||||
Citing decisions: |
|
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t060462eu1.html
Date retrieved: 17 May 2021
6 references found.
Click X to load a reference inside the current page, click on the title to open in a new page.EPC Implementing Rules
Case Law Book: III Amendments
XCLR III C 6.3 Final date for written submissions in the preparation for oral proceedings and late submission of new facts and evidence – Rule 116 EPC